FDA Requests More Data After Reviewing IsoRay’s Application for GammaTile Radiation Therapy

FDA Requests More Data After Reviewing IsoRay’s Application for GammaTile Radiation Therapy
IsoRay, a company specializing in the treatment of prostate and other cancers, has received a response from the U.S. Food and Drug Administration (FDA) regarding the company’s pending 510(k) application for its GammaTile radiation therapy system. Following a review, the FDA said IsoRay and its co-applicant GammaTile needed to submit additional data within the next 180

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *